OncoMatch/Clinical Trials/NCT03363373
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Is NCT03363373 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies GM-CSF + Naxitamab for neuroblastoma.
Treatment: GM-CSF + Naxitamab — Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroblastoma
Demographics
Prior therapy
Cannot have received: systemic anti-cancer therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Florida · Gainesville, Florida
- University of Chicago · Chicago, Illinois
- Riley Hospital for Children · Indianapolis, Indiana
- Memorial Sloan Kettering Cancer Center · New York, New York
- Nationwide Children's Hospital · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03363373 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-cancer therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages